Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 BATs and Pembrolizumab in Metastatic Breast Cancer
NCT03272334Phase 2Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Dec 2017
- Primary completion
- Nov 2024
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of HER2Bi-armed activated T cells in breast cancer (3 arms), sponsored by University of Virginia. Primary endpoint: Dose Limiting Toxicities at 10 weeks. Started Dec 2017; status: active, not recruiting.
02
Drugs
HER2Bi-armed activated T cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03272334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272334.